Navigation Links
The Leukemia & Lymphoma Society and Anjin Group Announce Multi-Year Collaborative Research Agreement
Date:4/16/2008

New Partnership under LLS's Therapy Acceleration Program to Advance

Development of a Treatment for Acute Myelogenous Leukemia

WHITE PLAINS, N.Y., April 16 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Anjin Group, Inc. today jointly announced the execution of a three-year collaborative research arrangement funded through LLS's Therapy Acceleration Program (TAP).

The arrangement provides for $2.9 million to accelerate the development of a fusion toxin protein for the treatment of acute myelogenous leukemia (AML). Continued funding will be contingent on meeting certain milestones during the course of the partnership. This partnership marks the first drug development alliance announced under TAP, an innovative program intended to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers.

"As a company dedicated to rapid development of a drug class with significant potential for the treatment of blood cancers and a number of other severe disorders, Anjin Group is very pleased to have the sponsorship of LLS," said Bill Harrison, Chief Executive Officer of Anjin Group. "This is a significant collaboration for us, and we hope to repay LLS through the development and commercialization of therapies capable of treating a variety of blood cancers."

Louis J. DeGennaro, Ph.D., Chief Scientific Officer of LLS, added, "Our partnership with Anjin Group, the largest announced to date under LLS's Therapy Acceleration Program, is the result of a detailed, year-long selection process. By dedicating a portion of LLS's research funding to a select group of highly motivated, well positioned commercial organizations, coupled with active engagement, development services and clearly crafted milestones, we hope to assist those organizations in speeding effective therapies to our patients. As a results-oriented, patient-focused company with a genuine interest in hematological cancers, Anjin Group aligns very well with the goals of TAP and we look forward to working with them."

About Anjin Group

Anjin Group, with operations in Maryland and Massachusetts, is a biotechnology company developing a broad-based therapeutic platform for blood cancers, brain cancer and other diseases based on the fusion of a modified form of diphtheria toxin to proteins capable of selectively targeting cancerous and diseased cells. The Company's technology can be deployed with a variety of cell surface receptors which are preferentially expressed on certain cell types in order to develop therapies with greater specificity and fewer side effects than existing drugs. For more information, see http://www.anjingroup.com.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the LLS Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif

914.821.8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
4. September is Leukemia, Lymphoma and Myeloma Awareness Month
5. The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
6. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
7. Leukemia Drug Proves Safe and Effective Over the Long Term
8. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
9. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
10. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
11. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
(Date:7/10/2017)... 2017 Locus Biosciences Inc. today announced the ... development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the round ... Internet services provider, and joined by the North Carolina ... product programs targeting antibiotic resistant infections and other microbiome-related ... Dr. Rodolphe Barrangou and Dr. Charles ...
Breaking Medicine Technology:
(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... ... a $1.5 million Health Resources and Services Administration (HRSA) grant to train predoctoral ... special health care needs in rural and underserved areas. , The Predoctoral Pediatric ...
(Date:7/20/2017)... ... 19, 2017 , ... A July 7th article ... varicose veins in some patients, according to medical experts. Washington State medical clinic ... excessive sitting or standing, or regularly nicking yourself while shaving your legs, and ...
(Date:7/18/2017)... ... 18, 2017 , ... CannaKids, a California Cooperative Cooperation that specializes in the ... the WORLDZ Summit, taking place in Hollywood from July 31-August 1, the Company’s ... cannabis for both pediatric and adult patients, and how the path has led her ...
(Date:7/18/2017)... ... July 18, 2017 , ... The results of an international clinical trial, led in part by ... severe type of muscular dystrophy holds promise for a subgroup of patients. , In a ... and colleagues at 53 study sites in 18 countries describe the clinical benefit of using ...
(Date:7/18/2017)... ... July 18, 2017 , ... An inventor from Seattle, Wash., has developed ... to clean, scrub and moisturize the back and other hard-to-reach areas of the body. ... movement in my upper body, particularly my shoulders. I found it difficult to reach ...
Breaking Medicine News(10 mins):